Ailevi Akdeniz Ateşi Olan 40 Gebenin Perinatal Sonuçları

Year 2018, Volume: 49 Issue: 1, 77 - 79, 05.03.2018

Ebru Alıcı Davutoğlu Ayşegül Özel Hakan Erenel Rıza Madazlı

https://doi.org/10.16948/zktipb.333212

Abstract

Amaç
: Ailevi
Akdeniz Ateşi (AAA)  tanısı olan, gebe  olguların maternal ve fetal sonuçlarının
değerlendirilmesi amaçlanmıştır.

 

Gereç ve Yöntem :
Çalışmamız 2013-2017 yılları arasında üniversitemizin perinataloji kliniğinde
gebelikleri takip edilmiş 40 AAA olgusunun dosya verilerinin retrospektif olarak
incelenmesiyle yapıldı. Hastaların klinik özellikleri , obstetrik ve perinatal
sonuçları değerlendirildi.

 

Bulgular:
Ortalama
hasta yaşı 30.75 ±6.15, nulliparite oranı %42,5 bulundu. Ortalama hastalık
süresi 8,36 ± 5.44 yıl olarak bulundu. Gebelik sırasında 7 hasta atak geçirdi.
Hastaların % 90 ’ ı medikal tedavi almaktaydı. Ortalama doğum haftası 37,3±4.5,
ortalama doğum kilosu 3115±547  gr
bulundu. Preterm doğum, fetal büyüme kısıtlılığı  ,preeklampsi görülme oranları sırasıyla; %10 ,
%5 , %10, olarak bulundu. Fetal ve neonatal kayıp, ile konjenital anomalili
doğum gözlenmedi.

 

Sonuç  : AAA tanılı gebelik
olgularının yönetiminde multidisipliner yaklaşım ile takip ve tedavinin
sağlanması olumlu  maternal ve fetal
sonuçlar ile ilişkilidir.

Keywords

Ailevi Akdeniz Ateşi ; perinatal sonuçlar

Perinatal Outcomes of 40 Pregnancies with Familial Mediterranean Fever

Abstract

Objective
: To
evaluate maternal and fetal outcomes of  pregnancies diagnosed with Familial
Mediterranean Fever (FMF)

Methods
:  Retrospective analysis of 40 pregnancies
diagnosed with FMF who received antenatal care at our perinatology unit between
2012 -2017 included in this clinical study. Clinical characteristics of
patients, perinatal and maternal outcomes were evaluated.

Results
: The
mean patient age was 30.75 ±6.15 and the nulliparity rate was 42,5 %. The mean
duration of illness was found to be 8,36 ± 5.44 years. 7 patients had an attack
during pregnancy. 90 % of the patients received medical treatment. Mean gestational
age at delivery was 37,3±4.5 ,  mean birth weight was 3115±547 g.  Preterm delivery, fetal
growth restriction and  preeclampsia
rates were 10, 5, 10 % respectively. Fetal and neonatal loss, congenital
anomalous birth was not observed.

Conclusion:
Multidisciplinary approach to the care of 
pregnancy diagnosed with FMF  is
associated with good maternal and fetal outcomes.

Keywords

: Familial Mediterranean Fever ; perinatal outcome

References

• 1 Dormer AE, Hale JF. Familial Mediterranean fever: a cause of periodic fever Br. Med J. 1962 Jan ; 13 (1) :87-9
• 2 Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet 1998 Feb ;28 (351):659-64
• 3 Ben-Chetrit E, Levy M. Reproductive system in Familial Mediterranean fever: an overview. Ann Rheum Dis 2003 Oct ; 62 (10) :916–9.
• 4 Mijatovic V, Hompes PG, Wouters MG. Familial Mediterranean fever and its implications for fertility and pregnancy. Eur J Obstet Gynecol Reprod Biol 2003 Jun ; 10 (108):171–6
• 5 Tunca M, Akar S, Onen F, Ozdogan H, Kasapcopur O, Yalcinkaya F et al. Familial Mediterranean fever ) in Turkey: results of a nationwide multicenter study. Medicine 2005 Jan; 84 (1):1–11. 
 6 Cobankara V, Fidan G, Turk T, Zencir M, Colakoglu M, Ozen S The prevalence of familial Mediterranean fever in the Turkish province of Denizli: a field study with a zero patient design. Clin Exp Rheumatol 2004 Jul-Aug; 22 (4): 27–30.
• 7 Michael O, Goldman RD, Koren G. Safety of colchicine therapy during pregnancy. Can Fam Physician 2003 Aug; 49 :967–9.
• 8 Ben chetrit E, Levy M, Colchicine: 1998 update. Semin Arthritis Rheum 1998 Aug ;28 (1):48–59.
• 9 Berkenstadt M, Weisz B, Cuckle H, Di-Castro M, Guetta E, Barski G. Chromosomal abnormalities and birth defects among couples with colchicine treated Familial Mediterranean fever. Am J Obstet Gynecol 2005 Oct ;193 (4):1513–6
• 10 Ditkoff EC,Sauer MV.Successful pregnancy in a Familial Mediterranean fever patient following assisted reproduction. J Assist Reprod Genet 1996 Sep ;13 (8):684– 5.
• 11 Rabinovitch O, Zemer D, Kukua E, Sohar E, Mashiach S.Colchicine treatment in conception and pregnancy: 231 pregnancies with Familial Mediterranean fever. Am J Repord Immunol 1992 Oct - Dec ; 28 (3–4):245–6.
• 12 Zemer D, Pras M, Sohar E, Modan M,Cabili S, Gafni J. Colchicine in the prevention and 
treatment of the amyloidosis of familial Mediterranean fever. 
N Engl J Med 1986 Apr ;314 (16):1001–3.
• 13 Ofir D, Levy A, Wiznitzer A, Mazor M, Sheiner E Familial Mediterranean fever : An independent risk factor for preterm delivery European Journal of Obstetrics & Gynecology and Reproductive Biology 2008 Dec;141 (2) :115–118 14 Yasar 0, Iskender C, Kaymak O, Yaman TS, Uygur D, Danısman N Retrospective evaluation of pregnancy outcomes in women with familial Mediterranean fever J Matern Fetal Neonatal Med 2014 May; 27(7): 733–736 
 15 Ben-Cherit E, Ben-Cherit A, Berkun Y, Ben-Cherit E Pregnancy outcomes in women with familial Mediterranean fever receiving colchicine: is amniocentesis justified? Arthritis Care Res 2010 Feb; 62(2):143–148
• 16 Ehrenfeld M, Brzezinski A, Levy M, Eliakim M. Fertility and obstetric history in patients with familial Mediterranean fever on long-term colchicine therapy. Br J Obstet Gynaecol 1987 Dec; 94 (12):1186-91.
• 17 Ben-Chetrit E, Levy M. Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years. Semin Arthritis Rheum 1991 Feb; 20 (4):241-6.
• 18 Berkenstadt M, Weisz B, Cuckle H, Di-Castro M, Guetta E, Barkai G. Chromosomal abnormalities and birth defects among couples with colchicine treated familial Mediterranean fever. Am J Obstet Gynecol 2005 Oct ;193 (4):1513-6.
• 19 Venhoff N,Voll RE, Glaser C, Thiel J IL-1-blockade with Anakinra during pregnancy : Retrospective analysis of efficacy and safety in female patients with familial Mediterranean fever Z Rheumatol 2017 Jul ; Epub ahead of print
• 20 Ilgen U, Küçükşahin O Anakinra use during pregnancy: Report of a case with Familial Mediterranean Fever and infertility. Eur J Rheumatol 2017 Mar ; Epub ahead of print